CDSCO Labelling Reforms Seen as Boost for Safer, Globally Competitive Medicines

Indian pharmaceutical companies have welcomed the Central Drugs Standard Control Organisation’s (CDSCO) recent labelling reforms as a critical step toward enhancing patient safety and global alignment. Saransh Chaudhary, president of global critical care at Venus Remedies, noted that clearer, consistent labelling could transform how medicines are used in India and internationally.

Labelling and packaging issues—such as cluttered layouts, inconsistent placement of safety information, and hard-to-read instructions—have long posed risks to patients and healthcare professionals. Packaging not only preserves a medicine’s efficacy but also serves as the first line of defence against errors, counterfeiting, and misuse.

Globally, agencies like the US FDA, EMA, and Japan’s PMDA emphasize legible, traceable, and tamper-evident packaging. India has begun aligning with these standards, including mandating QR codes on high-risk medicines. Chaudhary highlighted that patient-centric design—intuitive layouts, high-contrast text, and clear separation of critical details—can reduce errors while helping Indian manufacturers meet international expectations.

12-01-2026